ATEM (Alvesco Non-interventional Study)
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component|
- Treatment success with Alvesco [ Time Frame: after 3 months ] [ Designated as safety issue: No ]Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: after 3 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2010|
|Study Completion Date:||August 2011|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Other Name: Ciclesonide
Show 80 Study Locations
|Study Director:||Ingrid Moll-Schüler, MD||Nycomed Pharma GmbH|